GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FluoroPharma Medical Inc (OTCPK:FPMI) » Definitions » Beta

FluoroPharma Medical (FluoroPharma Medical) Beta : -118.40 (As of Apr. 27, 2024)


View and export this data going back to 2008. Start your Free Trial

What is FluoroPharma Medical Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-04-27), FluoroPharma Medical's Beta is -118.40.


FluoroPharma Medical Beta Historical Data

The historical data trend for FluoroPharma Medical's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FluoroPharma Medical Beta Chart

FluoroPharma Medical Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.02 -0.22 -0.10 0.56

FluoroPharma Medical Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.10 0.48 0.43 0.65 0.56

Competitive Comparison of FluoroPharma Medical's Beta

For the Biotechnology subindustry, FluoroPharma Medical's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


FluoroPharma Medical's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FluoroPharma Medical's Beta distribution charts can be found below:

* The bar in red indicates where FluoroPharma Medical's Beta falls into.



FluoroPharma Medical Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


FluoroPharma Medical  (OTCPK:FPMI) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


FluoroPharma Medical Beta Related Terms

Thank you for viewing the detailed overview of FluoroPharma Medical's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


FluoroPharma Medical (FluoroPharma Medical) Business Description

Traded in Other Exchanges
N/A
Address
8 Hillside Avenue, Suite 108, Montclair, NJ, USA, 07042
FluoroPharma Medical Inc is a US-based biopharmaceutical company. It specializes in developing and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. The company focuses on the development of novel cardiovascular imaging agents which detect and assess acute and chronic forms of coronary artery disease (CAD). The company's clinical-stage molecular imaging pharmaceutical product candidates are 18-F TPP (BFPET) and 18-F FCPHA (CardioPET). The 18-F TPP is designed for use in stress-testing for patients with proven CAD whereas 18-F FCPHA is a molecular imaging agent which is designed to assess myocardial blood flow and metabolism in patients with CAD. The company operates in a single segment being Biopharmaceutical research and development.
Executives
Johan M. Spoor director, officer: CEO, PRESIDENT, CHAIRMAN 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116

FluoroPharma Medical (FluoroPharma Medical) Headlines

From GuruFocus